Ex-vivo organ culture as potential prioritization tool for breast cancer targeted therapy

References

• Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. 2016; 17;17(6):333–51. doi:10.1038/nrg.2016.49.
   PubMed Web of Science ®Google Scholar
• Carr TH, McEwen R, Dougherty B, Johnson JH, Dry JR, Lai Z, Ghazoui Z, Laing NM, Hodgson DR, Cruzalegui F, et al. Defining actionable mutations for oncology therapeutic development. Nat Rev Cancer. 2016; 26;16(5):319–29. doi:10.1038/nrc.2016.35.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Targeted Agent and Profiling Utilization Registry (TAPUR) Study. [accessed April; 2017], https://www.tapur.org.
   Google Scholar
• National Cancer Institute. Molecular Analysis for Therapy Choice (MATCH) Trial. [accessed April; 2017], https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match.
   Google Scholar
• Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart MJ, Sotiriou C, Ignatiadis M, Azim HA, Jr. The current use and attitudes towards tumor genome sequencing in breast cancer. Sci Rep. 2016; 02;6:22517. doi:10.1038/srep22517.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord JP, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34. doi:10.1016/S1470-2045(15)00188-6.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015;175(2):293–5. doi:10.1001/jamainternmed.2014.6300.
   PubMed Web of Science ®Google Scholar
• Meijer TG, Naipal KA, Jager A, van Gent DC. Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Sci OA. 2017;3(2):FSO190. doi:10.4155/fsoa-2017-0003.
   PubMed Web of Science ®Google Scholar
• Brijwani N, Jain M, Dhandapani M, Zahed F, Mukhopadhyay P, Biswas M, Khatri D, Radhakrishna VD, Majumder B, Radhakrishnan P, et al. Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. Sci Rep. 2017; 04;7(1):1502. doi:10.1038/s41598-017-01566-x.
   PubMedGoogle Scholar
• Donnadieu J, Lachaier E, Peria M, Saidak Z, Dakpe S, Ikoli JF, Chauffert B, Page C, Galmiche A. Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies. BMC Cancer. 2016 ;16;16:273. doi:10.1186/s12885-016-2318-x.
   PubMed Web of Science ®Google Scholar
• Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Dietz A, Bechmann I. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer. 2014; 21;110(2):479–88. doi:10.1038/bjc.2013.700.
   PubMed Web of Science ®Google Scholar
• Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 27;6:6169. doi:10.1038/ncomms7169.
   PubMed Web of Science ®Google Scholar
• Merz F, Gaunitz F, Dehghani F, Renner C, Meixensberger J, Gutenberg A, Giese A, Schopow K, Hellwig C, Schafer M, et al. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol. 2013;15(6):670–81. doi:10.1093/neuonc/not003.
   PubMed Web of Science ®Google Scholar
• Naipal KA, Verkaik NS, Sanchez H, van Deurzen CH, den Bakker MA, Hoeijmakers JH, Kanaar R, Vreeswijk MP, Jager A, van Gent DC. Tumor slice culture system to assess drug response of primary breast cancer. BMC Cancer. 2016; 09;16:78. doi:10.1186/s12885-016-2119-2.
   PubMed Web of Science ®Google Scholar
• Roife D, Dai B, Kang Y, Perez MVR, Pratt M, Li X, Fleming JB. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2016; 15;22(24):6021–30. doi:10.1158/1078-0432.CCR-15-2936.
   PubMed Web of Science ®Google Scholar
• Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, Majumder PK, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nat Commun. 2015; 11;6:6139. doi:10.1038/ncomms7139.
   PubMed Web of Science ®Google Scholar
• Radovich M, Kiel PJ, Nance SM, Niland EE, Parsley ME, Ferguson ME, Jiang G, Ammakkanavar NR, Einhorn LH, Cheng L, et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. Oncotarget. 2016; 30;7(35):56491–500. doi:10.18632/oncotarget.10606.
   PubMed Web of Science ®Google Scholar
• Zick A, Peretz T, Lotem M, Hubert A, Katz D, Temper M, Rottenberg Y, Uziely B, Nechushtan H, Meirovitz A, et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. Medicine (Baltimore). 2017;96(20):e6931. doi:10.1097/MD.0000000000006931.
   PubMed Web of Science ®Google Scholar
• Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, et al. The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. NPJ Breast Cancer. 2017;3:23. doi:10.1038/s41523-017-0026-6. PMID:28685159.
   PubMed Web of Science ®Google Scholar